Companies / Lyell Immunopharma, Inc.

Lyell Immunopharma, Inc.

Nasdaq: LYELCIK 1806952SOUTH SAN FRANCISCO, CA

Financials · FY2025

Revenue$36.0K
Net income$-274.45M
Total debt
Cash$72.98M
Diluted EPS$-16.06
Shares outstanding24.5M

Ownership

24.5M shares outstanding · as of Aug 3, 2026
0.51%Insiders
Ownership
Insiders0.51%124,248
10%+ / strategic11.64%2,853,056
Institutions53.42%13,091,101
Public float34.43%8,436,736

% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.

Insiders 23

View all →
Insider% of sharesShares
5.82%1,426,528
5.82%1,426,528
Seely LynnCEOPresident and CEO · Director
0.30%73,878
Hill Stephen J.Chief Operating Officer
0.07%17,795
Lee Gary K.Chief Scientific Officer
0.07%16,938
Bulis Veronica SanchezVP, Corporate Controller
0.06%15,637

Institutional holders 69

View all →
HolderValue% of shares
ARCH Venture Management, LLC$65.14M13.25%
MWG Caph Ltd$31.03M4.11%
Gsk PLC$30.34M6.17%
Vanguard Group Inc$25.44M3.37%
Foresite Capital Management IV, LLC$24.64M3.27%
Orland Properties Ltd$23.23M3.08%
Almitas Capital LLC$17.78M2.36%
Foresite Capital Management V, LLC$14.68M1.95%
venBio Partners LLC$10.39M1.38%
BlackRock, Inc.$10.18M2.96%

Activity

Jun 30, 2026View all →
InsidersInstitutions
Who's accumulating and trimming this stock (13F).
DateActorActionSecurityValueShares ΔPosition afterImpact
Q1 2026
as of
ARCH Venture Management, LLC
13F manager
AddCommon Stock$9.79M+488K
+17.69%
3,247,162
13.25% of shares
medium
Q1 2026
as of
Millennium Management LLC
13F manager
AddCommon Stock$8.03M+400K
+682.43%
458,905
1.87% of shares
medium
Q2 2026
as of
BlackRock, Inc.
13F manager
AddCommon Stock$7.62M+543K
+298.35%
724,342
2.96% of shares
medium
Q2 2026
as of
State Street Corporation
13F manager
AddCommon Stock$1.88M+134K
+260.04%
185,322
0.76% of shares
low
Q1 2026
as of
Renaissance Technologies LLC
13F manager
AddCommon Stock$1.54M+77K
+194.79%
116,411
0.48% of shares
low
Q1 2026
as of
Marshall Wace, LLP
13F manager
AddCommon Stock$1.51M+75K
+102.57%
148,516
0.61% of shares
low
Q1 2026
as of
RBF Capital, LLC
13F manager
TrimCommon Stock$-611.6K-30K
-40.88%
44,094
0.18% of shares
low
Q4 2025
as of
Barclays PLC
13F manager
AddCommon Stock$454.8K+15K
+1239.51%
15,967
0.07% of shares
low

Securities

via CUSIP / OpenFIGI
SymbolTypeMarketCUSIPFIGI
LYELCommon StockEquity55083R203BBG00RNXFN14